KR20210073515A - 췌장염을 치료하는 방법 - Google Patents

췌장염을 치료하는 방법 Download PDF

Info

Publication number
KR20210073515A
KR20210073515A KR1020217008242A KR20217008242A KR20210073515A KR 20210073515 A KR20210073515 A KR 20210073515A KR 1020217008242 A KR1020217008242 A KR 1020217008242A KR 20217008242 A KR20217008242 A KR 20217008242A KR 20210073515 A KR20210073515 A KR 20210073515A
Authority
KR
South Korea
Prior art keywords
antibody
pancreatitis
functional fragment
seq
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217008242A
Other languages
English (en)
Korean (ko)
Inventor
대니엘 디. 앵글
데이비드 에이. 투베슨
Original Assignee
콜드스프링하버러보러토리
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 콜드스프링하버러보러토리 filed Critical 콜드스프링하버러보러토리
Publication of KR20210073515A publication Critical patent/KR20210073515A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020217008242A 2018-09-10 2019-09-09 췌장염을 치료하는 방법 Ceased KR20210073515A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862729354P 2018-09-10 2018-09-10
US62/729,354 2018-09-10
PCT/US2019/050262 WO2020055768A1 (en) 2018-09-10 2019-09-09 Methods for treating pancreatitis

Publications (1)

Publication Number Publication Date
KR20210073515A true KR20210073515A (ko) 2021-06-18

Family

ID=69776851

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217008242A Ceased KR20210073515A (ko) 2018-09-10 2019-09-09 췌장염을 치료하는 방법

Country Status (13)

Country Link
US (1) US12378320B2 (https=)
EP (1) EP3849605A4 (https=)
JP (1) JP7560445B2 (https=)
KR (1) KR20210073515A (https=)
CN (2) CN120267815A (https=)
AU (1) AU2019337564A1 (https=)
BR (1) BR112021004444A2 (https=)
CA (1) CA3112382A1 (https=)
CL (2) CL2021000585A1 (https=)
IL (1) IL281343A (https=)
MX (1) MX2021002761A (https=)
SG (1) SG11202102416SA (https=)
WO (1) WO2020055768A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202102416SA (en) 2018-09-10 2021-04-29 Cold Spring Harbor Laboratory Methods for treating pancreatitis
US20250297027A1 (en) * 2021-01-12 2025-09-25 Yeda Research And Development Co. Ltd. Antibodies to cancer glycosylation and uses thereof
JP2024511189A (ja) * 2021-03-26 2024-03-12 ビオンテック・ソシエタス・エウロパエア がんの処置における抗ｃａ１９－９抗体およびｆｏｌｆｉｒｉｎｏｘを用いた組合せ療法。
US20250302409A1 (en) * 2024-03-26 2025-10-02 Hepatiq, Inc. Determining pancreas disease using functional imaging

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4471057A (en) 1981-06-30 1984-09-11 The Wistar Institute Detection of colorectal carcinoma
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
JPS63159763A (ja) * 1986-12-24 1988-07-02 Fujirebio Inc 逆受身凝集反応試薬
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
US7238715B2 (en) 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
HUE026444T2 (en) 2005-08-05 2016-05-30 Araim Pharmaceuticals Inc Tissue protection peptides and their use
FI20070853A0 (fi) * 2007-11-09 2007-11-09 Glykos Finland Oy Glykaania sitovat monoklonaaliset vasta-aineet
WO2009094172A2 (en) 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
JP5919604B2 (ja) 2008-08-08 2016-05-18 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 抗膵癌抗体
EP3385277A1 (en) 2013-03-15 2018-10-10 F. Hoffmann-La Roche AG Il-22 polypeptides and il-22 fc fusion proteins and methods of use
HK1223298A1 (zh) 2013-07-17 2017-07-28 阿拉伊姆药品公司 预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物
KR102313341B1 (ko) * 2013-08-26 2021-10-18 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
CN104623639A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 白介素22二聚体在制备治疗胰腺炎药物中的应用
PT3097122T (pt) 2014-01-24 2020-07-21 Ngm Biopharmaceuticals Inc Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
SG11202102416SA (en) 2018-09-10 2021-04-29 Cold Spring Harbor Laboratory Methods for treating pancreatitis

Also Published As

Publication number Publication date
EP3849605A4 (en) 2022-06-15
CN113056286A (zh) 2021-06-29
EP3849605A1 (en) 2021-07-21
CL2022000091A1 (es) 2022-11-18
CL2021000585A1 (es) 2021-08-13
IL281343A (en) 2021-04-29
US20220049011A1 (en) 2022-02-17
CA3112382A1 (en) 2020-03-19
SG11202102416SA (en) 2021-04-29
BR112021004444A2 (pt) 2021-06-01
AU2019337564A1 (en) 2021-05-06
US12378320B2 (en) 2025-08-05
MX2021002761A (es) 2021-05-31
CN113056286B (zh) 2025-04-29
CN120267815A (zh) 2025-07-08
JP2022500382A (ja) 2022-01-04
JP7560445B2 (ja) 2024-10-02
WO2020055768A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
RU2707882C2 (ru) Нацеленное на gpc3 лекарственное средство, которое вводят пациенту, чувствительному к нацеленной на gpc3 лекарственной терапии
US20110027186A1 (en) Taz/wwtr1 for diagnosis and treatment of cancer
JP7560445B2 (ja) 膵炎を処置するための方法
KR102240417B1 (ko) 항-트랜스티레틴 인간 항체
US9790503B2 (en) VHZ for diagnosis and treatment of cancer
JP5756014B2 (ja) がんの診断および治療のためのｖｈｚ
US20170334982A1 (en) Inflammatory Disease Treatment Composition Including Anti-Myosin Regulatory Light-Chain Polypeptide Antibody
JP2021531007A (ja) Ｖｉｓｔａに対する受容体
US20190292256A1 (en) Compounds and Methods to Measure Metabolic Function and Restore Normal Metabolic Function
RU2839356C2 (ru) Способы лечения панкреатита
US20240174765A1 (en) Anti- enolase 1 (eno1) antibody and applications thereof
US20140140998A1 (en) Cleavage inhibitors of transforming growth factor beta type i receptor and uses thereof in cancer therapy
CA3151199A1 (en) Stabilized c-fms intracellular fragments (ficd) promote osteoclast differentiation and arthritic bone erosion
WO2025217258A1 (en) Nptx1 antibodies
US20250353904A1 (en) Preventative Agent or Therapeutic Agent for Amyotrophic Lateral Sclerosis, Parkinson's Disease, Huntington's Disease, Spinocerebellar Ataxia, Aging-Related Degenerative or Neurological Disease, Brain Aging, or Diseases Associated With Brain Aging
JP2021097682A (ja) Ｃａｒｄ１４を用いた治療、診断およびスクリーニング
Hinkofer Distinction of vasculitis-associated ANCA subsets and their pathogenic role in a new mouse model with the humanized target antigen

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601